To eliminate every malignant cell, an anticancer drug must overcome many formidable obstacles presented by a tumor mass.
The drug must travel through the tumor's intricate network of blood vessels and disperse through the vessel walls into the interstitum - an area inside the tumor that is rich in a tough connective tissue protein called collagen. From there, the drug must enter directly into cancer cells, which typically occupy less than 50% of the total volume of a tumor.
Unfortunately, the cancer cell has an abundance of defense mechanisms to block the full penetration of
What makes CHML exceptional is that its molecule is 33,000 times smaller than normal cells, enabling it to penetrate into the tumor mass. But more importantly, this facilitates its permeation directly into the cancer cell itself. Once it enters the cell, CHML is able to induce apoptosis (or "programmed cancer cell death").
CHML has been called a biological, "cancer seeking missile". CHML is a patented Biological composition consisting of: squalene, unsaturated & saturated fatty acids, and liposoluable vitamins. All components of CHML are extracted from natural sources and formulated using biological lipid-activated
Remarkable anti-cancer activity has been demonstrated both in vitro and in-vivo, and the compound was affirmed to be highly stable in extensive tests performed in multiple esteemed laboratories in both the U.S., and other in countries.
The following video demonstrates the destruction of cancer cells by CHML in real-time. The cancer type shown in the video is Sarcomas - 180 cells, with a concentration of 1 million cells per mL. These cells were added into a dish containing CHML at the concentration of 10 mg/mL. A sample of this mixture was immediately placed on a piece of glass and observed under a microscope. In just 1 minute and 43 seconds, cancer cells were destroyed by CHML.
According to reports of clinical trials at Phase II and Phase III, CHML does not cause hair loss, vomiting, diarrhea, mucosistis, leukopenia, thrombocytopenia, and anemia.
According to the reports of clinical trials at Phase II and Phase III, CHML has shown to cause tumor cell to shrink or disappear, using CT, MRI, or Ultrasonic examination.